Improving mRNA vaccine safety and efficiency with cationized lipid nanoparticle formula
暂无分享,去创建一个
Yan Zhang | Hailin Yin | Yan Zhang | Guangneng Liao | Guang Yang | Xiujin Wu | Guang Yang | Xu Peng | Kai Xu | Yucheng Zhou | Yaoyi Zhang | Chen-Bin He | Dongsheng Ren | Yingxue Lei | Liang Chen | Hailin Yin | Yingxue Lei
[1] D. Weissman,et al. Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer , 2023, Science advances.
[2] T. Nakayama,et al. Comparison of cytokine production in mice inoculated with messenger RNA vaccines BNT162b2 and mRNA‐1273 , 2022, Microbiology and immunology.
[3] Y. Lou,et al. Structural and biochemical characteristics of mRNA nanoparticles determine anti–SARS-CoV-2 humoral and cellular immune responses , 2022, Science advances.
[4] K. Loré,et al. Innate immune mechanisms of mRNA vaccines , 2022, Immunity.
[5] Xiaohong Song,et al. Comparative immunogenicity analysis of intradermal versus intramuscular immunization with a recombinant human adenovirus type 5 vaccine against Ebola virus , 2022, Frontiers in Immunology.
[6] Wael Al-Jaroudi,et al. COVID-19 vaccine-associated myocarditis , 2022, World journal of cardiology.
[7] Xiangrong Song,et al. mRNA Vaccines Against SARS‐CoV‐2 Variants Delivered by Lipid Nanoparticles Based on Novel Ionizable Lipids , 2022, Advanced functional materials.
[8] L. Hartling,et al. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review , 2022, BMJ.
[9] T. Shimabukuro,et al. Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe , 2022, The Lancet Infectious Diseases.
[10] K. Whitehead,et al. The replacement of helper lipids with charged alternatives in lipid nanoparticles facilities targeted mRNA delivery to the spleen and lungs. , 2022, Journal of controlled release : official journal of the Controlled Release Society.
[11] Yi-Tao Yu,et al. The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines , 2021, Frontiers in Cell and Developmental Biology.
[12] Daniel L. Roellinger,et al. Myocarditis Following Coronavirus Disease 2019 mRNA Vaccine: A Case Series and Incidence Rate Determination , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] Aaron M. Rosenfeld,et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses , 2021, Immunity.
[14] K. Khunti,et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection , 2021, Nature Medicine.
[15] C. Bogdan,et al. Reactogenicity Correlates Only Weakly with Humoral Immunogenicity after COVID-19 Vaccination with BNT162b2 mRNA (Comirnaty®) , 2021, Vaccines.
[16] D. Weissman,et al. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration , 2021, Communications Biology.
[17] S. Ciesek,et al. Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies , 2021, Journal of clinical medicine.
[18] B. Igyártó,et al. The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory , 2021, bioRxiv.
[19] D. Peer,et al. Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles. , 2021, ACS nano.
[20] N. Tchitchek,et al. Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific Immune Response , 2020, Frontiers in Immunology.
[21] J. Mascola,et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.
[22] P. Dormitzer,et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine , 2020, The New England journal of medicine.
[23] Gustavo Lou,et al. Manufacturing Considerations for the Development of Lipid Nanoparticles Using Microfluidics , 2020, Pharmaceutics.
[24] E. Walsh,et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates , 2020, The New England journal of medicine.
[25] C. Roberts,et al. Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic lipid selection. , 2020, Journal of controlled release : official journal of the Controlled Release Society.
[26] A. Vojdani,et al. Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases , 2020, Clinical Immunology.
[27] A. Amanullah,et al. Myocardial injury and COVID-19: Possible mechanisms , 2020, Life Sciences.
[28] Qiang Cheng,et al. Selective ORgan Targeting (SORT) nanoparticles for tissue specific mRNA delivery and CRISPR/Cas gene editing , 2020, Nature Nanotechnology.
[29] Huijun Lu,et al. mRNA Vaccines Encoding the HA Protein of Influenza A H1N1 Virus Delivered by Cationic Lipid Nanoparticles Induce Protective Immune Responses in Mice , 2020, Vaccines.
[30] Kimberly J. Hassett,et al. Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines , 2019, Molecular therapy. Nucleic acids.
[31] D. Weissman,et al. Zika virus protection by a single low dose nucleoside modified mRNA vaccination , 2017, Nature.
[32] Daniel G. Anderson,et al. Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination , 2016, Proceedings of the National Academy of Sciences.
[33] D. Weissman,et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. , 2015, Journal of controlled release : official journal of the Controlled Release Society.
[34] K. G. Rajeev,et al. Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.